DK2659000T3 - Forbedret deponering af chromogener under anvendelse af pyrimidinanaloger - Google Patents
Forbedret deponering af chromogener under anvendelse af pyrimidinanaloger Download PDFInfo
- Publication number
- DK2659000T3 DK2659000T3 DK11813853.6T DK11813853T DK2659000T3 DK 2659000 T3 DK2659000 T3 DK 2659000T3 DK 11813853 T DK11813853 T DK 11813853T DK 2659000 T3 DK2659000 T3 DK 2659000T3
- Authority
- DK
- Denmark
- Prior art keywords
- enzyme
- dab
- sample
- target
- antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Claims (16)
1. Fremgangsmåde til påvisning af et mål i en prøve ved proksimal deponering af en markør, omfattende: at bringe prøven i kontakt med en genkendelsesopløsning , genkendelsesopløsningen omfatter en specifik bindingsgruppe specifik til målet; mærke den specifikke bindingsgruppe med et enzym; bringe prøven i kontakt med en påvisningsopløsning, påvisningsopløsningen omfattende et enzymatisk substrat så at markøren deponerer proksimalt til målet i tilstedeværelse af en deponeringsforstærker med en formel
hvor RI, R2, R3, og R4 uafhængigt er valgt fra alifatisk, aryl, halogen, en heteroatom-indeholdende gruppe, og hydrogen; RI og/eller R3 kan bindes til R2 for at danne et kondenseret, aromatisk ringsystem; A er valgt fra et carbonatom, et heteroatom udover svovl, og hvilke som helst kombination deraf; og påvisning af markøren.
2. Fremgangsmåden ifølge krav 1, hvor prøven bringes i kontakt med en påvisningsopløsning der omfatter enzymatisk oxidering af enzymsubstrat under anvendelse af et oxidringsmiddel til at danne markøren, hvor enzymatisk oxidering af enzymsubstratet under anvendelse af et oxideringsmiddel omfatter reducering af opløseligheden eller stabilitet af det enzymatiske substrat så at det enzymatiske substrat bliver deponeret som markøren.
3. Fremgangsmåden ifølge krav 2, hvor det enzymatiske substrat er valgt fra gruppen bestående af et chromogen- og et tyramid-konjugat.
4. Fremgangsmåden ifølge et hvilket som helst af kravene 1-3, hvor RI, R2, R3, og R4 er valgt fra hydrogen og hydroxyl og hver A er et carbonatom, eventuelt hvor RI, R3, og R4 er hydrogen og R2 er hydroxyl.
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1-3, hvor RI, R2, og R3 er uafhængigt valgt fra alkyl, alken, alkyn, hydrogen, iod, brom, chlor, fluor, og kombinationer deraf.
6. Fremgangsmåden ifølge et hvilket som helst af kravene 1-5, hvor enzymet er en oxidreduktase eller en peroxidase.
7. Fremgangsmåden ifølge et hvilket som helst af kravene 1-6, hvor den specifikke bindingsgruppe omfatter et antistof eller en nukleinsyre.
8. Fremgangsmåden ifølge et hvilket som helst af kravene 1-7, hvor enzymsubstratet er valgt fra 1,3-diaminobenzidin, 3-amino-9-ethylcarbazol, tetramethylbenzidin, fluorescein, luminophor, coumarin, BODIPY-farve, resorufin, rhodamin, eller et derivat deraf, eller hvor enzymsubstratet er et tyraminderivat.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 1-8, hvor detektionsopløsningen yderligere omfatter et accelereringsmiddel valgt fra en heteroarylforbindelse, en borsyre, en phenolforbindelse, eller en kombination deraf, eventuelt hvor heteroarylforbindelsen er valgt fra imidazol, L-histidin, pyridin-N-oxid, pyrimidin-N-oxid, N-methyl-morpholinoxid, og 2,2,6,6-tetramethylpiperidin-l-oxyl.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 1-9, hvor detektionsopløsningen yderligere omfatter en non-ionisk surfaktant valgt fra en polyoxyethylenlaurylether med en formel (C2H40)23C12H250H; polyoxyethylen (20) sorbitanmonoalkylat, monoalkylatet omfattende mellem 8 og 14 carbonatomer; en lineær sekundær alkohol-polyoxyethylen med en formel C12-14H25-290(CH2CH20]x, hvor x er lig med et heltal mellem 2 og 12; og polyoxyethylenoctylphenylether, eller hvor påvisningsopløsningen yderligere omfatter en antioxidant valgt fra natriumbisulfat, natriumstannat, natriummetabisulfat, og kombinationer deraf, eller hvor påvisningsopløsningen yderligere omfatter et Gruppe I eller Gruppe II metal-indeholdende salt med en formel MX2 eller MX hvor M er et Gruppe I eller Gruppe II metal valgt fra lithium, natrium, kalium, cæsium, calcium, magnesium, strontium, og barium; og X er valgt fra fluorid, chlorid, bromid, iodid, carbonat, hydroxid, og phosphat.
11. Anvendelse af et kit i en fremgangsmåde til påvisning af et mål, kittet omfattende et enzym; en påvisningsopløsning omfattende en deponeringsforstærker og et enzymsubstrat der producerer en detekterbar gruppe efter omsætning med enzymet, deponeringsforstærkeren har en formel,
hvor RI, R2, R3, og R4 uafhængigt er valgt fra alifatisk, aryl, halogen, en heteroatom-indeholdende gruppe, og hydrogen; RI og/eller R3 kan bindes til R2 for at danne et fusioneret, aromatisk ringsystem; A er valgt fra et carbonatom, et heteroatom udover svovl, og hvilke som helst kombination deraf.
12. Anvendelsen ifølge krav 11, hvor kittet yderligere omfatter en specifik bindingsgruppe, eventuelt hvor den specifikke bindingsgruppe er et antistof eller en nukleinsyre der specifikt binder til et målmolekyle.
13. Anvendelsen ifølge krav 12, hvor den specifikke bindingsgruppe og enzymet er bundet sammen.
14. Anvendelsen ifølge et hvilket som helst af kravene 11 til 13, hvor enzymet er oxidreduktase eller peroxidase, eventuelt hvor peroxidasen er peberrodsperoxidase eller glutathionperoxidase.
15. Anvendelsen ifølge et hvilket som helst af kravene 11 til 14, hvor enzymsubstratet er valgt fra 1,3-diaminobenzidin, 3-amino-9-ethylcarbazol, tetramethylbenzidin, fluorescein, luminophor, coumarin, BODIPY-farve, resorufin, rhodamin, eller et derivat deraf, eller hvor enzymsubstratet er et tyraminderivat.
16. Fremgangsmåden ifølge et hvilket som helst af kravene 1-10 eller anvendelsen ifølge et hvilket som helst af kravene 11-15, hvor deponeringsforstærkeren har en koncentration i området fra ca. 5 mM til ca. 15 mM og det enzymatiske substrat har en koncentration i området fra større end 0 mM til ca. 8 mM.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061460349P | 2010-12-30 | 2010-12-30 | |
| PCT/US2011/067481 WO2012092322A1 (en) | 2010-12-30 | 2011-12-28 | Enhanced deposition of chromogens utilizing pyrimidine analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2659000T3 true DK2659000T3 (da) | 2016-08-29 |
Family
ID=45554795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11813853.6T DK2659000T3 (da) | 2010-12-30 | 2011-12-28 | Forbedret deponering af chromogener under anvendelse af pyrimidinanaloger |
| DK16161377.3T DK3088534T3 (da) | 2010-12-30 | 2011-12-28 | Forbedret deponering af chromogener under anvendelse af pyridin-analoger |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16161377.3T DK3088534T3 (da) | 2010-12-30 | 2011-12-28 | Forbedret deponering af chromogener under anvendelse af pyridin-analoger |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8871442B2 (da) |
| EP (2) | EP3088534B1 (da) |
| JP (2) | JP5815046B2 (da) |
| KR (1) | KR101554795B1 (da) |
| CN (1) | CN103282516B (da) |
| AU (2) | AU2011352251B2 (da) |
| BR (1) | BR112013014360B8 (da) |
| CA (2) | CA2817374C (da) |
| DK (2) | DK2659000T3 (da) |
| ES (2) | ES2689593T3 (da) |
| HK (1) | HK1185634A1 (da) |
| IL (1) | IL226479A (da) |
| SG (2) | SG190892A1 (da) |
| WO (1) | WO2012092322A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817374C (en) * | 2010-12-30 | 2018-10-16 | Ventana Medical Systems, Inc. | Enhanced deposition of chromogens utilizing pyrimidine analogs |
| US9618429B2 (en) | 2012-01-23 | 2017-04-11 | Ventana Medical Systems, Inc. | Polymer stabilization of chromogen solutions |
| US10041950B2 (en) | 2012-03-27 | 2018-08-07 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
| ES2633864T3 (es) | 2012-09-24 | 2017-09-25 | Ventana Medical Systems, Inc. | Procedimiento para identificar cáncer de pulmón de células no pequeñas que responde al tratamiento usando quinasa de linfoma anaplásico (alk) como marcador |
| CN105164272A (zh) * | 2013-02-28 | 2015-12-16 | 株式会社日冷生物科学 | 使用标记酶的染色用含dab底物试剂盒 |
| CN105247348A (zh) | 2013-03-12 | 2016-01-13 | 文塔纳医疗***公司 | 用于多路化组织学的数字增强的显微镜检查 |
| US9689875B2 (en) | 2013-08-28 | 2017-06-27 | Ventana Medical Systems, Inc. | Immunohistochemical assay for detection of CD3 and CD16 |
| DK3111224T3 (da) * | 2014-02-24 | 2019-03-18 | Ventana Med Syst Inc | Quinonmethidanalog-signalforstærkning |
| CA2996798A1 (en) | 2015-08-28 | 2017-03-09 | Ventana Medical Systems, Inc. | Protein proximity assay in formalin fixed paffafin embedded tissue using caged haptens |
| US10718694B2 (en) * | 2016-04-18 | 2020-07-21 | Diagnostic Biosystems | Counterstains for a biological sample |
| JP7128121B2 (ja) | 2016-06-28 | 2022-08-30 | ヴェンタナ メディカル システムズ， インク． | Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用 |
| JP7021126B2 (ja) * | 2016-06-28 | 2022-02-16 | ヴェンタナ メディカル システムズ， インク． | マルチ色素キノンメチド及びチラミドコンジュゲートによる発色性ｉｈｃ及びｉｓｈ染色のための新規の色 |
| CN110785654A (zh) | 2017-06-28 | 2020-02-11 | 文塔纳医疗***公司 | ***级校准 |
| EP3853214A1 (en) | 2018-09-20 | 2021-07-28 | Ventana Medical Systems, Inc. | Coumarin-based crosslinking reagents |
| JP2020071152A (ja) | 2018-10-31 | 2020-05-07 | ソニー株式会社 | 免疫染色方法、免疫染色システム、および免疫染色キット |
| JP2023538753A (ja) | 2020-08-28 | 2023-09-11 | ヴェンタナ メディカル システムズ， インク． | 検出可能な部分を含むコンジュゲート |
| EP4217393A1 (en) | 2020-09-22 | 2023-08-02 | Ventana Medical Systems, Inc. | Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin |
| EP4278181A1 (en) | 2021-01-15 | 2023-11-22 | Ventana Medical Systems, Inc. | Storage stable caged haptens |
| EP4281779A1 (en) | 2021-01-25 | 2023-11-29 | Ventana Medical Systems, Inc. | Stained biological specimens including one or more biomarkers labeled with one or more detectable moieties |
| WO2022223137A1 (en) | 2021-04-18 | 2022-10-27 | Ventana Medical Systems, Inc. | Morphological marker staining |
| WO2024137817A1 (en) | 2022-12-23 | 2024-06-27 | Ventana Medical Systems, Inc. | Materials and methods for evaluation of antigen presentation machinery components and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1564604A (en) | 1925-06-12 | 1925-12-08 | Chas S Hodges | Water wheel |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4318984A (en) * | 1979-11-13 | 1982-03-09 | Miles Laboratories, Inc. | Stabilized composition, test device, and method for detecting the presence of a sugar in a test sample |
| GB8713951D0 (en) | 1987-06-15 | 1987-07-22 | Dewar M H | Enhanced chemiluminescent reaction |
| WO1990003370A1 (en) * | 1988-09-28 | 1990-04-05 | Microprobe Corporation | DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE |
| US5595707A (en) | 1990-03-02 | 1997-01-21 | Ventana Medical Systems, Inc. | Automated biological reaction apparatus |
| US5225325A (en) * | 1990-03-02 | 1993-07-06 | Ventana Medical Systems, Inc. | Immunohistochemical staining method and reagents therefor |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| GB9306888D0 (en) * | 1993-04-01 | 1993-05-26 | Kricka Larry J | Chemiluminescent enhancers |
| JPH07308200A (ja) * | 1994-05-16 | 1995-11-28 | Konica Corp | ペルオキシダーゼ様物質の活性または酸化性物質の検出及び測定のための組成物並びに測定方法 |
| KR0164072B1 (ko) | 1995-11-13 | 1999-02-01 | 김주용 | 반도체 소자의 얕은 접합 형성방법 |
| AU4980097A (en) * | 1996-10-21 | 1998-05-15 | University Of Iowa Research Foundation, The | Efficient synthesis of nucleosides |
| US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
| WO1999044030A1 (en) | 1998-02-27 | 1999-09-02 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| US6582962B1 (en) | 1998-02-27 | 2003-06-24 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| US20030211630A1 (en) | 1998-02-27 | 2003-11-13 | Ventana Medical Systems, Inc. | Automated molecular pathology apparatus having independent slide heaters |
| DE19834938C2 (de) | 1998-07-29 | 2000-07-20 | Coty Bv | Verfahren zur kosmetischen Bräunungsbestimmung einer Selbstbräunungszusammensetzung und Test-Kit |
| US6372937B1 (en) | 1998-11-09 | 2002-04-16 | Mark Norman Bobrow | Enhanced catalyzed reporter deposition |
| US6355443B1 (en) * | 1999-03-17 | 2002-03-12 | Mark Norman Bobrow | 4-(4-hydroxystyryl) pyridine-containing substrates for an analyte dependent enzyme activation system |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020076732A1 (en) * | 2000-12-15 | 2002-06-20 | Kaplan David R. | Methods for detecting an analyte of interest using catalyzed reporter deposition of tyramide |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
| US6617125B2 (en) * | 2001-06-29 | 2003-09-09 | Perkinelmer Life Sciences, Inc. | Compositions for enhanced catalyzed reporter deposition |
| JP4567436B2 (ja) | 2001-07-20 | 2010-10-20 | ライフ テクノロジーズ コーポレーション | 発光ナノ粒子およびそれらの調製方法 |
| US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
| ATE437369T1 (de) | 2003-06-24 | 2009-08-15 | Ventana Med Syst Inc | Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen |
| CA2817374C (en) * | 2010-12-30 | 2018-10-16 | Ventana Medical Systems, Inc. | Enhanced deposition of chromogens utilizing pyrimidine analogs |
-
2011
- 2011-12-28 CA CA2817374A patent/CA2817374C/en active Active
- 2011-12-28 US US13/339,066 patent/US8871442B2/en active Active
- 2011-12-28 BR BR112013014360A patent/BR112013014360B8/pt active IP Right Grant
- 2011-12-28 CA CA3007179A patent/CA3007179C/en active Active
- 2011-12-28 DK DK11813853.6T patent/DK2659000T3/da active
- 2011-12-28 DK DK16161377.3T patent/DK3088534T3/da active
- 2011-12-28 SG SG2013040589A patent/SG190892A1/en unknown
- 2011-12-28 AU AU2011352251A patent/AU2011352251B2/en active Active
- 2011-12-28 JP JP2013547631A patent/JP5815046B2/ja active Active
- 2011-12-28 EP EP16161377.3A patent/EP3088534B1/en active Active
- 2011-12-28 WO PCT/US2011/067481 patent/WO2012092322A1/en active Application Filing
- 2011-12-28 ES ES16161377.3T patent/ES2689593T3/es active Active
- 2011-12-28 EP EP11813853.6A patent/EP2659000B1/en active Active
- 2011-12-28 SG SG10201804238TA patent/SG10201804238TA/en unknown
- 2011-12-28 ES ES11813853.6T patent/ES2593464T3/es active Active
- 2011-12-28 KR KR1020137016695A patent/KR101554795B1/ko active IP Right Grant
- 2011-12-28 CN CN201180062801.5A patent/CN103282516B/zh active Active
-
2013
- 2013-05-21 IL IL226479A patent/IL226479A/en active IP Right Grant
- 2013-11-20 HK HK13112956.2A patent/HK1185634A1/xx unknown
-
2014
- 2014-10-06 US US14/507,447 patent/US9435795B2/en active Active
-
2015
- 2015-06-17 JP JP2015122090A patent/JP6130438B2/ja active Active
- 2015-07-30 AU AU2015207891A patent/AU2015207891B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015207891B2 (en) | Enhanced deposition of chromogens utilizing pyrimidine analogs | |
| US20210341466A1 (en) | Colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates | |
| EP2334827B1 (en) | Method for chromogenic detection of two or more target molecules in a single sample | |
| JP2019532012A (ja) | Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用 | |
| JP7033122B2 (ja) | ケージドハプテンを使用するホルマリン固定パラフィン包埋組織におけるタンパク質近接アッセイ | |
| JP2017531797A (ja) | ポリマー及びポリマーを含むコンジュゲート |